Zhang Y, Wang Y, Chen Z, Cheng S, Ding C, Zhang J
Toxicol Res (Camb). 2021; 10(2):334-344.
PMID: 33884183
PMC: 8045597.
DOI: 10.1093/toxres/tfab008.
Vincenzi B, Trower M, Duggal A, Guglielmini P, Harris P, Jackson D
BMJ Open. 2020; 10(2):e030114.
PMID: 32034016
PMC: 7045265.
DOI: 10.1136/bmjopen-2019-030114.
Qin H, Wang F, Wang K, Liu H, Guo R, Zeng Z
Ann Transl Med. 2019; 7(3):54.
PMID: 30906758
PMC: 6389580.
DOI: 10.21037/atm.2019.01.02.
Kilic A, Harder A, Reich H, Knie U, Masur C, Abels C
Clin Cosmet Investig Dermatol. 2018; 11:591-602.
PMID: 30538520
PMC: 6251459.
DOI: 10.2147/CCID.S172518.
Emrick J, Mathur A, Wei J, Gracheva E, Gronert K, Rosenblum M
Proc Natl Acad Sci U S A. 2018; 115(51):E12091-E12100.
PMID: 30463955
PMC: 6305010.
DOI: 10.1073/pnas.1814132115.
[Cutaneous side effects of targeted cancer drugs].
Below J, Homey B, Gerber P
Hautarzt. 2016; 68(1):12-18.
PMID: 27885401
DOI: 10.1007/s00105-016-3902-3.
Mechanisms of skin aging induced by EGFR inhibitors.
Gerber P, Buhren B, Schrumpf H, Hevezi P, Bolke E, Sohn D
Support Care Cancer. 2016; 24(10):4241-8.
PMID: 27165055
PMC: 5611667.
DOI: 10.1007/s00520-016-3254-7.
Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.
Belum V, Washington C, Pratilas C, Sibaud V, Boralevi F, Lacouture M
Pediatr Blood Cancer. 2015; 62(5):798-806.
PMID: 25683226
PMC: 4376610.
DOI: 10.1002/pbc.25429.
[Drug reactions caused by chemotherapy agents].
Ehmann L, Schrumpf H, Gerber P, Homey B
Hautarzt. 2014; 65(5):443-9.
PMID: 24820802
DOI: 10.1007/s00105-013-2699-6.
Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.
Ensslin C, Rosen A, Wu S, Lacouture M
J Am Acad Dermatol. 2013; 69(5):708-720.
PMID: 23981682
PMC: 4181350.
DOI: 10.1016/j.jaad.2013.06.038.
Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy.
Mascia F, Lam G, Keith C, Garber C, Steinberg S, Kohn E
Sci Transl Med. 2013; 5(199):199ra110.
PMID: 23966299
PMC: 6324537.
DOI: 10.1126/scitranslmed.3005773.
Dermatological adverse events from BRAF inhibitors: a growing problem.
Belum V, Fischer A, Choi J, Lacouture M
Curr Oncol Rep. 2013; 15(3):249-59.
PMID: 23463215
DOI: 10.1007/s11912-013-0308-6.
Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients.
Gerber P, Meller S, Eames T, Buhren B, Schrumpf H, Hetzer S
Eur J Med Res. 2012; 17:4.
PMID: 22472354
PMC: 3351712.
DOI: 10.1186/2047-783X-17-4.
Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.
Peuvrel L, Bachmeyer C, Reguiai Z, Bachet J, Andre T, Bensadoun R
Support Care Cancer. 2012; 20(5):909-21.
PMID: 22361824
DOI: 10.1007/s00520-012-1404-0.
Rosacea: The cytokine and chemokine network.
Gerber P, Buhren B, Steinhoff M, Homey B
J Investig Dermatol Symp Proc. 2011; 15(1):40-7.
PMID: 22076326
PMC: 3704141.
DOI: 10.1038/jidsymp.2011.9.
